Japan-based Toray Industries has concluded a licensing agreement with Acologix, a California-based biopharmaceutical company specializing in the field of osteo-renal diseases, for AC-200 (phosphatonin), a drug candidate being developed by Acologix. AC-200 is a recombinant protein intended for the treatment of hyperphosphatemia. Under the agreement, Toray will have an exclusive license to AC-200 in Japan.

Hyperphosphatemia, which is a common symptom of patients in the terminal or advanced stages of chronic renal failure, induces severe conditions like cardiovascular episodes and bone disease.